numbers raised at Oppenheimer. Shares of CSCO now seen reaching $32. Estimates also increased, following positive channel checks. Outperform rating.
(DG - Get Report)
price target boosted at BofA/Merrill. DG price target raised to $36 from $30 on consistent execution and growth prospects. Reiterate Buy rating.
estimates, target upped at Morgan Stanley. Shares of DOV now seen reaching $63. Company is seeing higher order trends and deserves a higher multiple. Overweight rating.
estimates raised at Goldman. GLW estimates were increased through 2012. Inventory remains tight in the LCD supply chain. Buy rating.
Hudson City Bancorp
numbers lowered at FBR. HCBK estimates were cut through 2011. Company is seeing slower balance sheet growth. Outperform rating and new $15 price target.
estimates, target raised at UBS. Shares of HON now seen reaching $47. Estimates also increased, given better end-market demand and M&A opportunities. Neutral rating.
numbers raised at Morgan Stanley. Shares of IR now seen reaching $38. Estimates also increased, given stronger orders. Equal-weight rating.
numbers lowered at Goldman. Estimates were cut through 2012. Company will likely faces rising costs. Neutral rating and new $50 price target.
(NKE - Get Report)
estimates, target increased at Goldman. NKE estimates were raised through 2012. Company likely to talk up accelerating growth trends at its upcoming investor meeting. Buy rating and new $85 price target.
price target raised at BofA/Merrill. ORLY price target lifted to $52 from $46 as 1Q10 is expected to benefit from early spring and DC progress. Maintain Buy rating.
numbers boosted at Goldman. Shares of PCX now seen reaching $25. Estimates also upped, given the company's new production guidance and lower expected costs. Sell rating.
estimates, target upped at Goldman. RTN estimates were boosted through 2012. Company will likely repurchase more shares. Neutral rating and new $52 price target.
target, estimates boosted at Citi. SLB price target jumped to $92 from $84 as the international recovery is ahead of expectations. 2010 and 2011 EPS estimates lifted to $2.95 and $3.65, respectively. Maintain Buy rating.